Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02 2021 - 4:01PM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases, today
announced the closing of its initial public offering of 13,953,332
shares of common stock, which includes the exercise in full by the
underwriters of their option to purchase 1,819,999 additional
shares, at an initial public offering price of $15.00 per
share. The aggregate gross proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by Icosavax, were $209.3 million. Icosavax’s
common stock is listed on the Nasdaq Global Select Market under the
ticker symbol “ICVX.”
Jefferies, Cowen, Evercore ISI and William Blair acted as joint
book-running managers for the offering.
Registration statements relating to the offering have been filed
with the Securities and Exchange Commission and became effective on
July 28, 2021. A prospectus relating to and describing the terms of
the offering has been filed with the SEC and is available on the
SEC’s website at www.sec.gov. The offering was made only by means
of a prospectus. Copies of the final prospectus may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by email at Prospectus_Department@Jefferies.com or by telephone at
877-821-7388; from Cowen and Company, LLC, c/o Broadridge Financial
Solutions, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, or by email at
PostSaleManualRequests@broadridge.com or by telephone at
833-297-2926; from Evercore Group L.L.C., Attention: Equity Capital
Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055,
or by email at ecm.prospectus@evercore.com or by telephone at
888-474-0200; or from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, or by email at prospectus@williamblair.com or by
telephone at 800-621-0687.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its
innovative VLP platform technology to develop vaccines against
infectious diseases, with an initial focus on life-threatening
respiratory diseases. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s pipeline includes vaccine candidates targeting
respiratory syncytial virus (RSV), human metapneumovirus (hMPV),
and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Icosavax was formed in 2017 to advance the breakthrough VLP
technology from the Institute for Protein Design at the University
of Washington with the goal to discover, develop, and commercialize
vaccines against infectious diseases. Icosavax exclusively licensed
the VLP technology for use in several fields, including RSV and
hMPV, from the University of Washington. For SARS-CoV-2, Icosavax
has a non-exclusive, worldwide (excluding South Korea) license from
the University of Washington that will convert to an exclusive
license in North America and Europe in 2025. Icosavax is located in
Seattle.
Contact:
For Media Only: Jessica Yingling, Ph.D.Little
Dog Communications Inc.jessica@litldog.com+1.858.344.8091
Icosavax Investor Contact:Laurence
WattsGilmartin Group,
LLClaurence@gilmartinir.com+1.619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Apr 2023 to Apr 2024